Business Wire

Vifor Pharma’s Ferinject ® granted new recommendations in updated 2021 ESC heart failure guidelines

Share

Regulatory News:

Vifor Pharma is pleased to announce that the European Society of Cardiology (ESC) included new recommendations and proposals in the 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure for two of their key products, Ferinject® and Veltassa®.

With regard to iron deficiency, the following new recommendations for HF patients with reduced function of the heart are added:

  • Periodic screening for iron deficiency is recommended in all HF patients (Class I).
  • Ferinject® should be considered to reduce the risk of HF hospitalizations in symptomatic HF patients with iron deficiency (Class IIa).
  • Ferinject® should be considered before and early after discharge in patients who have been hospitalized with acute heart failure and with iron deficiency to improve HF symptoms and reduce risk of re-hospitalizations (Class IIa).

The existing recommendation to consider Ferinject® in patients with HF and iron deficiency to alleviate HF symptoms, improve exercise capacity and quality of life remains unchanged (Class IIa designation). The results of the AFFIRM-AHF study are reflected in the update of the ESC guidelines. Ferinject® remains the only intravenous (i.v.) iron therapy specifically mentioned in the new ESC HF guidelines.

The guidelines also propose that the use of potassium binder agents like Veltassa® may allow RAAS inhibitor initiation or uptitration in a larger proportion of heart failure patients. In patients with chronic or recurrent hyperkalemia on RAAS inhibitor therapy Veltassa®may as well be initiated to maintain the patients on guidelines recommended doses of RAAS inhibitors. The new proposals further describe the unique evidence for RAASi enabling generated by Veltassa® through the clinical trials.

“We are very pleased with the new recommendations to the ESC’s guidelines in heart failure and are grateful for this development for the patients,” commented Klaus Henning Jensen, Chief Medical Officer of Vifor Pharma. “With improved diagnosis rates of iron deficiency and enabling RAASi, more patients can benefit from treatment. Reducing the risk of heart failure hospitalizations and improving symptoms are key therapeutic goals in the treatment of heart failure. We are particularly pleased by the consideration of Ferinject® and Veltassa® in the new treatment guidelines to achieve these therapeutic goals and believe this will enable us to further expand our role in helping heart failure patients with iron deficiency and hyperkalemia live better, healthier lives.”

The ESC HF guidelines aim to provide practical, evidence-based recommendations for the diagnosis and treatment of HF, thereby improving and harmonizing standards of diagnosis and treatment of cardiovascular diseases for physicians, and potentially optimizing patient care. The ESC HF guidelines are updated periodically, with the 2021 version published at the virtual ESC congress end of August 2021.

The 2021 ESC guidelines are published under: www.escardio.org/Guidelines

About Vifor Pharma Group
Vifor Pharma Group is a global pharmaceuticals company. It aims to become the global leader in iron deficiency, nephrology and cardio-renal therapies. The company is a partner of choice for pharmaceuticals and innovative patient-focused solutions. Vifor Pharma Group strives to help patients around the world with severe and chronic diseases lead better, healthier lives. The company develops, manufactures and markets pharmaceutical products for precision patient care. Vifor Pharma Group holds a leading position in all its core business activities and consists of the following companies: Vifor Pharma and Vifor Fresenius Medical Care Renal Pharma (a joint company with Fresenius Medical Care). Vifor Pharma Group is headquartered in Switzerland, and listed on the Swiss Stock Exchange (SIX Swiss Exchange, VIFN, ISIN: CH0364749348).

For more information, please visit viforpharma.com.

About AFFIRM-AHF
The AFFIRM-AHF study was a multi-center, randomized, double-blind, placebo-controlled trial, comparing the effect of intravenous ferric carboxymaltose (FCM) on hospitalizations and mortality in iron deficient patients admitted for acute heart failure. The study demonstrated that administration of Ferinject® reduced the risk of HF hospitalizations and improved quality of life with no apparent effect on the risk of cardiovascular death.

About Ferinject®
Ferinject®/Injectafer® (ferric carboxymaltose) is a leading i.v. iron therapy with market authorization in 84 countries by the end of June 2021. More than 16 million patient years of experience have helped to establish Ferinject®/ Injectafer® as a trusted brand, with clinical benefits demonstrated by its efficacy and safety data2.

About Veltassa®
Veltassa® (patiromer) is a potassium binder approved for the treatment of hyperkalemia. Veltassa® was specially designed to exchange calcium rather than sodium for potassium ions, ensuring suitability for patients who cannot tolerate even small increases in sodium. Veltassa® should not replace emergency treatment for life-threatening hyperkalemia.

References:
1 Anker, S.,D. (2018). Effects of ferric carboxymaltose on hospitalisations and mortality rates in iron-deficient heart failure patients: an individual patient meta-analysis. Eur J Heart fail. 20(1):125-133. doi: 1002/ejhf.823.
2 Scott Drugs. 2018 Mar;78(4):479–493. doi: 10.1007/ s40265-018-0885-7.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media Relations
Nathalie Ponnier
Global Head Corporate Communications
+41 79 957 96 73
media@viforpharma.com

Investor Relations
Julien Vignot
Head of Investor Relations
+41 58 851 66 90
investors@viforpharma.com

About Business Wire

Business Wire
Business Wire



Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

New Conviva Data Reveals How Consumers Discover Streaming Content – And the Implications for Publishers20.9.2021 18:55:00 CEST | Press release

Conviva, the intelligence cloud for streaming media, released its State of Streaming: Content Discovery report for 2021 today, revealing how consumers find new streaming content to watch. The report showed content streamed for the first time was discovered in four ways: word of mouth (59%), advertising (52%), social media (49%) and streaming service recommendations (43%). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210920005788/en/ Conviva's State of Streaming Content Discovery (Graphic: Business Wire) “Given the incredible amount of streaming content available today, connecting viewers with content that not only piques their interest, but also resonates enough to keep them coming back for more is a significant challenge for publishers looking to identify and engage new audiences,” said Keith Zubchevich, CEO, Conviva. “By leveraging advertising, recommendations and social media to curate and promote their offerings, publi

Tiedemann-koncernen och Alvarium Investments aviserar transaktion för att bilda Alvarium Tiedemann Holdings och listas på Nasdaq via företagsförvärv med Cartesian Growth Corporation20.9.2021 18:46:00 CEST | Pressmeddelande

Tiedemann-koncernen1 (”Tiedemann”), Alvarium Investments Limited2 (”Alvarium”) och Cartesian Growth Corporation3 (”Cartesian”) (NASDAQ: GLBL) meddelade idag gemensamt ikraftträdande av ett slutligt rörelseförvärvsavtal (”Rörelseförvärvsavtalet”). Den här föreslagna transaktionen kommer att skapa Alvarium Tiedemann Holdings, som förväntas vara ett ledande, oberoende globalt investeringsföretag som tillhandahåller institutioner, entreprenörer, familjer och nästa generations kommande ledare med förvaltnings- och investeringsstrategier och -tjänster. De konstituerande företagens expansiva internationella nätverk över fyra kontinenter, mångsidiga expertis och tillgång till privat och institutionellt kapital förväntas erbjuda en attraktiv portfölj av tjänster. Detta omfattande erbjudande kommer att understrykas av ett åtagande att påverka eller värdejustera investeringar och erbjuda betrodda rådgivningstjänster till familjeägda företag samt direkt- och saminvesteringsmöjligheter för realtill

Verimatrix To Debut New App Monitoring SaaS Service at Money 20/20 Europe20.9.2021 17:45:00 CEST | Press release

Regulatory News: Verimatrix, (Euronext Paris: VMX) (Paris:VMX), the leader in powering the modern connected world with people-centered security, today announced it’s scheduled to unveil a new mobile application monitoring service, an extension of its award-winning App Shield and Code Protection solutions, during this week’s Money 20/20 Europe in-person event. Taking place September 21-23 in booth D140 at RAI Amsterdam, Verimatrix’s launch of its security monitoring service for mobile applications can assist both new and existing customers in gaining the intelligence and protections needed for mission-critical apps. The new monitoring solution is available for both Verimatrix App Shield and Verimatrix Code Protection. App Shield is a no-code SaaS service that brings unprecedented cybersecurity protection to any Android or iOS app. Developers simply upload their app to the Verimatrix App Shield platform and receive a secured version that’s ready to publish to an app store, a critical las

Citi, IFC and Global Bank Partner to Finance Women’s Economic Empowerment in Panama20.9.2021 16:08:00 CEST | Press release

Citi, Global Bank and the International Finance Corporation (IFC) have partnered to provide more mortgages and Small Medium Enterprise (SME) business loans to women. The joint initiative offers a first-of-its-kind co-lending transaction of a $90 million loan ($20 million funded by Citi for three years and $70 million funded by IFC for five years) to Global Bank. The proceeds from this loan will be used for either Low Income Housing Mortgages–Hipoteca Preferencial–for women as heads of household or for women-owned and-or women-led enterprises. In addition, Global Bank will also partner with IFC Advisory Services to further enhance and develop gender-focused products and services in Panama. “It’s an honor to support groups and institutions that seek to broaden women empowerment across the region as well as to place women at the center of Panama’s recovery from the coronavirus pandemic,” said Marcelo Gorrini, Caribbean and Central America Cluster Head and Panama Citi Country Officer. “Thi

WilsonHCG Recognized as a “Leader” in Contingent Workforce Solutions and MSP by NelsonHall20.9.2021 16:00:00 CEST | Press release

WilsonHCG has been identified as a “Leader” in NelsonHall’s 2021 NEAT Vendor Evaluation and Assessment Tool for Managed Service Program (MSP) and Contingent Workforce Services (CWS) providers. “Being ranked as a Leader for our contingent workforce services is a testament to listening to our clients’ needs and differentiating by providing a high-touch experience that’s often overlooked in this space. The team is committed to exceptional service and it shows,” said John Wilson, CEO, WilsonHCG. “Organizations are looking for a variety of talent solutions in this challenging market and we’re proud to offer contingent workforce services that give them access to the talent they need to succeed.” Nikki Edwards, Principal Research Analyst with NelsonHall’s HR Technology & Services practice, added, “WilsonHCG applies a high-touch and personalized approach to its range of next-generation contingent workforce solutions (with a broad range of service expertise and use of cutting-edge tech), enabli

EMGA Advises Landmark US$300M Debt Raise for BTG Pactual With DFC20.9.2021 16:00:00 CEST | Press release

Emerging Markets Global Advisory Limited (EMGA), the niche investment bank focused on emerging markets, announces today a landmark Senior Debt capital raise transaction that will allow BTG Pactual to expand its small and medium-sized enterprise (SME) activities in Brazil. The US$300 million debt facility was provided by DFC and the transaction is the largest Senior Debt facility ever advised by EMGA and follows on from a US$140 million transaction completed last year with DEG and Proparco, two European development institutions. The operation comes at a time when banks world-wide are exploring new cross-border funding options to further deliver on their support to businesses affected by the COVID-19 pandemic. Commenting on the transaction, BTG Pactual’s Caio Zanette said, “BTG Pactual is very pleased with the support of EMGA on pursuing this landmark transaction that will benefit our SME activities in Brazil. We continue to develop all our activities and the funding provided by DFC will

White Oak Buys Finacity in Flagship Acquisition20.9.2021 15:00:00 CEST | Press release

White Oak Global Advisors (“White Oak”) has completed the acquisition of Finacity Corporation (“Finacity”) a global leader in working capital and trade finance funding solutions to global businesses. Finacity originates, structures and places over USD$100 billion in trade finance receivables yearly with over 50 leading financial institutions in asset-backed security structures. Finacity has facilitated transactions for receivables denominated in 58 currencies with obligors in more than 175 countries making it the largest non-bank trade finance platform globally. The deal will see Adrian Katz remain as Finacity CEO and substantive equity holder, working closely with the leadership of White Oak Global Advisors. With this acquisition White Oak and its affiliates will have over 215 professionals focused on asset-based lending offering trade receivables securitization and a variety of ABL products including invoice discounting, factoring, trade finance, supply chain finance, lender finance

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom